168 related articles for article (PubMed ID: 21819166)
1. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
[TBL] [Abstract][Full Text] [Related]
2. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
3. US insurance program's experience with a multigene assay for early-stage breast cancer.
Hornberger J; Chien R; Krebs K; Hochheiser L
Am J Manag Care; 2011 May; 17(5 Spec No):e194-202. PubMed ID: 21711071
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
5. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Lyman GH; Cosler LE; Kuderer NM; Hornberger J
Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan.
Kondo M; Hoshi SL; Ishiguro H; Yoshibayashi H; Toi M
Breast Cancer Res Treat; 2008 Nov; 112(1):175-87. PubMed ID: 18075786
[TBL] [Abstract][Full Text] [Related]
7. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
Kondo M; Hoshi SL; Yamanaka T; Ishiguro H; Toi M
Breast Cancer Res Treat; 2011 Jun; 127(3):739-49. PubMed ID: 21082239
[TBL] [Abstract][Full Text] [Related]
9. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
Lamond NW; Skedgel C; Rayson D; Lethbridge L; Younis T
Breast Cancer Res Treat; 2012 Jun; 133(3):1115-23. PubMed ID: 22361999
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
Hornberger J; Cosler LE; Lyman GH
Am J Manag Care; 2005 May; 11(5):313-24. PubMed ID: 15898220
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.
Kondo M; Hoshi SL; Ishiguro H; Toi M
Breast Cancer Res Treat; 2012 Jun; 133(2):759-68. PubMed ID: 22315134
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
[TBL] [Abstract][Full Text] [Related]
19. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
20. Economic and cost-effectiveness issues in breast cancer treatment.
Hillner BE
Semin Oncol; 1996 Feb; 23(1 Suppl 2):98-104. PubMed ID: 8614853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
